https://www.selleckchem.com/pr....oducts/crenolanib-cp
esent cost-effectiveness acceptability curves to compare a range of possible cost-effectiveness thresholds. The economic evaluation project had its project charter in June 2018 and is expected to be completed in September 2021. The final results will be available in the second half of 2021. We expect to assess whether CONEMO plus enhanced usual care is a cost-effective strategy to improve depressive symptoms in this population compared with enhanced usual care. This study will contribute to the evidence base for health mana
Like
Comment
Share
